Brno Epilepsy Centre, First Department of Neurology, St. Anne's Teaching Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Acta Neurol Scand. 2010 Feb;121(2):83-8. doi: 10.1111/j.1600-0404.2009.01257.x. Epub 2009 Dec 10.
To assess the long-term efficacy and tolerability of levetiracetam in routine clinical practice.
We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months. The primary points evaluated were: long-term retention rate, reasons for discontinuing levetiracetam and the percentage of seizure-free patients.
The retention rate at 6, 12, 24 and 36 months following the commencement of levetiracetam treatment was 91.7, 75.2, 60.1 and 53.7% respectively. Sixty-seven (30.7%) patients discontinued levetiracetam treatment. During the clinical audit evaluation period, surgical resection or implantation of VNS was performed in 31 (14.3%) patients. In 53 of the 67 patients (79.1%), the treatment was discontinued due to lack of efficacy; in 14 patients (20.9%) treatment was discontinued due to adverse events. In total, 24 of 218 patients (11.0%) were seizure-free for 36 months.
Levetiracetam is an effective and well-tolerated option for long-term treatment of epilepsy in adults.
评估左乙拉西坦在常规临床实践中的长期疗效和耐受性。
我们回顾性分析了 218 例患者，主要为成年人，大多为局灶性相关癫痫，接受左乙拉西坦辅助治疗或单药治疗长达 36 个月。主要评估指标为：长期保留率、停止左乙拉西坦治疗的原因和无癫痫发作患者的比例。
左乙拉西坦治疗开始后 6、12、24 和 36 个月的保留率分别为 91.7%、75.2%、60.1%和 53.7%。67 例（30.7%）患者停止了左乙拉西坦治疗。在临床审核评估期间，31 例（14.3%）患者进行了手术切除或植入迷走神经刺激器。在 67 例患者中（79.1%），因缺乏疗效而停止治疗；14 例患者（20.9%）因不良反应而停止治疗。共有 24 例患者（11.0%）在 36 个月内无癫痫发作。
左乙拉西坦是成人癫痫长期治疗的一种有效且耐受性良好的选择。
